| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Stemazole targets stem cell survival pathways. It promotes the survival of human embryonic stem cells and maintains stemness. It promotes the survival of oligodendrocyte precursor cells in vitro. It significantly increases cell survival rate and clone formation number in a dose-dependent manner, and decreases the apoptosis rate. It may be used in studies of stem cell survival in starvation cultures.
|
|---|---|
| ln Vitro |
In vitro, Stemazole promotes the survival of human embryonic stem cells and maintains stemness. It promotes the survival of oligodendrocyte precursor cells in vitro. It significantly increases cell survival rate and clone formation number in a dose-dependent manner, and decreases the apoptosis rate. It enhances clonal expansion of single cells.
|
| ln Vivo |
In vivo, Stemazole promotes the recovery of motor dysfunction and the repair of myelin sheaths. It can be used as a therapeutic agent in demyelinating disorders, promoting OPC survival in vitro and regeneration in vivo. It promotes stem cell survival and has neuroprotective properties.
|
| Enzyme Assay |
The activity of Stemazole is assessed using cell-based assays with human embryonic stem cells (hESCs) or oligodendrocyte precursor cells (OPCs). Cells are treated with varying concentrations of Stemazole, and cell survival, proliferation, and apoptosis are measured. Clone formation assays are used to assess clonal expansion. The EC50 for promoting cell survival is determined from dose-response curves.
|
| Cell Assay |
To evaluate the cellular effects of Stemazole, stem cells or progenitor cells are treated with the compound. Cell viability is assessed using standard assays such as MTT or trypan blue exclusion. Apoptosis is measured using Annexin V/PI staining or caspase activity assays. The maintenance of stemness is assessed by analyzing the expression of pluripotency markers.
|
| Animal Protocol |
In vivo studies with Stemazole typically involve administration to animal models via oral or intraperitoneal routes. In models of demyelinating disorders, the compound's effects on motor function recovery and myelin repair are assessed. Its neuroprotective effects are evaluated in models of neurodegeneration.
|
| ADME/Pharmacokinetics |
Stemazole has a molecular formula of C9H9N5OS2 and a molecular weight of 267.34 g/mol. Its CAS number is 317337-07-8. It is a small molecule compound. The purity is typically >98%. It should be stored according to the manufacturer's instructions.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for Stemazole are not extensively detailed in the available literature. However, its use in animal models at effective doses suggests a degree of tolerability. As with all research compounds, standard safety precautions should be taken when handling Stemazole. It is intended for research use only and is not for human consumption.
|
| References | |
| Additional Infomation |
Stemazole is a protective agent that promotes stem cell survival. It is a novel small molecule human stem/progenitor cell proliferation activator. Stemazole promotes the survival of human embryonic stem cells and oligodendrocyte precursor cells. It can be used as a therapeutic agent in demyelinating disorders. It is a research tool for studying stem cell biology, neuroprotection, and regenerative medicine.
|
| Molecular Formula |
C9H9N5OS2
|
|---|---|
| Molecular Weight |
267.330657720566
|
| Exact Mass |
267.024
|
| CAS # |
317337-07-8
|
| PubChem CID |
3876544
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
452.7±55.0 °C at 760 mmHg
|
| Flash Point |
227.6±31.5 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.762
|
| LogP |
2.02
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
351
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
NNC(NC1=CC=C(C2=NN=C(S)O2)C=C1)=S
|
| InChi Key |
DSZWZHYEFYRNQI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H9N5OS2/c10-12-8(16)11-6-3-1-5(2-4-6)7-13-14-9(17)15-7/h1-4H,10H2,(H,14,17)(H2,11,12,16)
|
| Chemical Name |
1-amino-3-[4-(2-sulfanylidene-3H-1,3,4-oxadiazol-5-yl)phenyl]thiourea
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~374.1 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.35 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (9.35 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7407 mL | 18.7035 mL | 37.4070 mL | |
| 5 mM | 0.7481 mL | 3.7407 mL | 7.4814 mL | |
| 10 mM | 0.3741 mL | 1.8703 mL | 3.7407 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
